Back to dashboard
All PlansCoverageMedium impact

Molecular Testing for Germline Variants Associated with Ovarian Cancer (BRIP1, RAD51C, RAD51D, NBN)

Blue Cross & Blue Shield of Mississippi·MS · Oncology, OB-GYN, Family Medicine +1 more·Medical Policy
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

This is a new medical policy establishing coverage guidelines for molecular testing of germline variants in four genes (BRIP1, RAD51C, RAD51D, NBN) associated with ovarian cancer risk. The policy provides background on ovarian cancer genetics and testing methodology but appears to be incomplete as it cuts off mid-sentence without stating the actual coverage determination or billing requirements.

Action Required

Action needed
Review the complete policy document when available to determine coverage criteria, billing requirements, and any prior authorization needs for genetic testing panels that include BRIP1, RAD51C, RAD51D, and NBN genes. Monitor for the full policy text as this document appears incomplete.

Related policy hubs